Anti-RUNX2 antibody (ab11906)
- Product nameAnti-RUNX2 antibodySee all RUNX2 primary antibodies ...
- DescriptionRabbit polyclonal to RUNX2
- Tested applicationsEMSA more details
- Species reactivityReacts with: Mouse, Human
Synthetic peptide: TDVPRRISDDDTATSD, corresponding to amino acids 333-348 of Human AML3/Runx2.
- Positive controlSaos-2 nuclear extract.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.1% Sodium Azide and 0.01% Thiomerosal.
Constituents: PBS containing 0.2% Gelatin.
- PurityWhole antiserum
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab11906 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|EMSA||EMSA: Use at an assay dependent dilution.|
- FunctionTranscription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
- Tissue specificitySpecifically expressed in osteoblasts.
- Involvement in diseaseDefects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
- Sequence similaritiesContains 1 Runt domain.
- DomainA proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
modificationsPhosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340.
- Cellular localizationNucleus.
- Acute myeloid leukemia 3 protein antibodyalpha subunit 1 antibodyAML3 antibody
- CBF alpha 1 antibodyCBF-alpha-1 antibodyCBFA1 antibodyCCD antibodyCCD1 antibodycleidocranial dysplasia 1 antibodyCore binding factor antibodyCore binding factor runt domain alpha subunit 1 antibodyCore binding factor subunit alpha 1 antibodycore-binding factor antibodyCore-binding factor subunit alpha-1 antibodyMGC120022 antibodyMGC120023 antibodyOncogene AML 3 antibodyOncogene AML-3 antibodyOSF 2 antibodyOSF-2 antibodyOSF2 antibodyOsteoblast specific transcription factor 2 antibodyOsteoblast-specific transcription factor 2 antibodyOTTHUMP00000016533 antibodyPEA2 alpha A antibodyPEA2-alpha A antibodyPEA2aA antibodyPEBP2 alpha A antibodyPEBP2-alpha A antibodyPEBP2A1 antibodyPEBP2A2 antibodyPEBP2aA antibodyPEBP2aA antibodyPEBP2aA1 antibodyPolyomavirus enhancer binding protein 2 alpha A subunit antibodyPolyomavirus enhancer-binding protein 2 alpha A subunit antibodyrunt domain antibodyRunt related transcription factor 2 antibodyrunt-related transcription factor 2 antibodyRUNX2 antibodyRUNX2_HUMAN antibodySL3 3 enhancer factor 1 alpha A subunit antibodySL3-3 enhancer factor 1 alpha A subunit antibodySL3/AKV core binding factor alpha A subunit antibodySL3/AKV core-binding factor alpha A subunit antibody
Anti-RUNX2 antibody images
Nushift polyclonal antibody against AML3 factor creates a supershift in EMSA (lane 4).
References for Anti-RUNX2 antibody (ab11906)
This product has been referenced in:
- Meyer KB et al. Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer. PLoS Biol 6:e108 (2008). EMSA ; Human . Read more (PubMed: 18462018) »
- Wang X et al. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology 148:1629-37 (2007). WB ; Mouse . Read more (PubMed: 17185377) »